Compare NFG & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFG | HALO |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.8B |
| IPO Year | 1997 | 2001 |
| Metric | NFG | HALO |
|---|---|---|
| Price | $96.13 | $63.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $91.20 | $78.18 |
| AVG Volume (30 Days) | 636.1K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.28% | N/A |
| EPS Growth | ★ 576.19 | N/A |
| EPS | 1.98 | ★ 2.56 |
| Revenue | ★ $2,277,541,000.00 | $151,862,000.00 |
| Revenue This Year | $13.10 | $28.24 |
| Revenue Next Year | $31.56 | $12.79 |
| P/E Ratio | $47.38 | ★ $24.83 |
| Revenue Growth | ★ 17.11 | N/A |
| 52 Week Low | $69.93 | $47.50 |
| 52 Week High | $94.69 | $82.22 |
| Indicator | NFG | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 75.62 | 28.72 |
| Support Level | $85.48 | $61.23 |
| Resistance Level | N/A | $65.40 |
| Average True Range (ATR) | 1.89 | 1.87 |
| MACD | 0.20 | -0.73 |
| Stochastic Oscillator | 95.66 | 5.17 |
National Fuel Gas Co is a diversified energy company involved in natural gas production, gathering, transportation, distribution, and marketing. It operates through three segments: Integrated Upstream and Gathering, Pipeline and Storage, and Utility. The majority of revenue comes from the Integrated Upstream and Gathering segment, which focuses on Seneca's natural gas exploration and development in the Appalachian region and Midstream operations supporting gas processing and gathering. The Pipeline and Storage segment transports and stores natural gas for customers in the northeastern United States and Canada, while the Utility segment supplies natural gas to retail customers in western New York and northwestern Pennsylvania. the company opeartes in United States.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.